InnoPharmax, Inc. announced that its licensing partner, Shandong New Time Pharmaceutical Co., Ltd., has received marketing authorization in Spain for Sapropterin dihydrochloride tablets, a product licensed from InnoPharmax. The approval marks a concrete step forward in the product’s development in the European market.
   For InnoPharmax, the Spain approval represents an important regulatory milestone for its licensed product overseas. It also reflects the Company’s continued efforts to extend product value through licensing partnerships, while strengthening the foundation for broader European market development and the international commercialization potential of its licensed assets.
   InnoPharmax will continue to pursue international licensing, co-development, and regional market partnerships to advance products with market potential across different regions, broaden the value of its product portfolio, and support the Company’s long-term growth.

   Official LinkedIn: https://www.linkedin.com/feed/update/urn:li:activity:7493881122498588672